[Edaily Reporter Kwon Oh Seok ] #ROKIT HEALTHCARE Inc.’s stock price has surged for two consecutive days. This is believed to be due to a surge in buying interest following news that its wholly-owned U.S. subsidiary has entered the final stage of its listing on the Nasdaq Global Market.

According to MP Doctor on the 25th, ROKIT HEALTHCARE Inc.’s stock was trading at 53,000 won as of 9:03 a.m., up 10.42% from the previous trading day.
The previous day, the company issued a press release stating, “ROKIT America, Inc. (Nasdaq ticker: RKAM), a wholly-owned U.S. subsidiary established in 2019, has successfully completed the procedures related to Form S-1 with the U.S. Securities and Exchange Commission (SEC) and has entered the final stage of its listing on the Nasdaq Global Market.”
The completion of the SEC Form S-1 process signifies that the company has cleared the most critical hurdle for entering the U.S. capital market. ROKIT America is currently awaiting the final outcome of its Nasdaq listing. Additionally, the company is successfully conducting a bookbuilding process with overseas institutional investors and plans to swiftly proceed with the remaining schedule, including the allocation of shares, the determination of the offering price, and the commencement of trading.
Based on the initial public offering price indicated in the registration statement currently filed with the SEC, Rokit America’s projected market capitalization at the time of listing is approximately 4000억 won. Once the listing is complete, Rokit America will become the first subsidiary of a KOSDAQ-listed South Korean biotech company to be listed on the Nasdaq Global Market and will use the 380억 won in investment funds expected to be secured locally to pioneer long-term regenerative clinical trials and markets in North and South America.